Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Temozolomide × Clear all

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms